Radium-223 dichloride is a radiopharmaceutical used to treat cancer that has metastasized to the bones, and whose effects are derived from both direct action of radiation on tumor cells as well as bystander effects caused by irradiation of both tumor and non-tumor cells in the bone microenvironment. Here, Canter and colleagues quantify the biological effects derived from both of these mechanisms of action. Direct effects from alpha particle irradiation (yellow arrows in the image at left) contribute to biological changes detected histologically in disseminated tumor cells and osteocytes within the range of the alpha particles. Bystander effects also contribute to biological changes in tumor cells beyond the range of the alpha particles emitted from the endosteal surface of the bone. These radiation-induced bystander effects can arise from tumor cells (white outlined arrow) and marrow cells (pink outlined arrow) within the range of alpha particles, and from bone cells (brown outlined...
Skip Nav Destination
Article navigation
1 October 2021
Highlights|
October 01 2021
Selected Articles from This Issue
Online Issn: 1557-3125
Print Issn: 1541-7786
©2021 American Association for Cancer Research
2021
American Association for Cancer Research
Mol Cancer Res (2021) 19 (10): 1611.
Related Content
This is a related article to:
Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow
This is a related article to:
Mice Deficient in the RNA-Binding Protein Zfp871 Are Prone to Early Death and Steatohepatitis in Part through the p53–Mdm2 Axis
This is a related article to:
Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2
This is a related article to:
MicroRNA-324-5p–CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness
- Views Icon Views
- Share Icon Share
-
Tools Icon
Tools
- Search Site
-
Article Versions Icon
Versions
- Version of Record October 1 2021
Citation
Selected Articles from This Issue. Mol Cancer Res 1 October 2021; 19 (10): 1611. https://doi.org/10.1158/1541-7786.MCR-19-10-HI
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Sign in via your Institution
Sign in via your InstitutionPay-Per-View Access
$50.00
11
Views
0
Citations
Citing articles via
Advertisement